Risk Management and Healthcare Policy
Dovepress open access to scientific and medical research
ORIGINAL RESEARCH
Open Access Full Text Article
Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies This article was published in the following Dove Press journal: Risk Management and Healthcare Policy 14 October 2016 Number of times this article has been viewed
Kelly F Bell Arie Katz John J Sheehan AstraZeneca, Wilmington, DE, USA
Correspondence: Kelly Bell Health Economics and Outcomes Research, AstraZeneca, US Medical Affairs, 1800 Concord Pike, PO Box 15437, Wilmington, DE, 19850, USA Tel + 1 267-417-6220 Email [email protected]
Background: The use of quality measures attempts to improve safety and health outcomes and to reduce costs. In two Phase III trials in treatment-naive patients with type 2 diabetes, dapagliflozin 5 or 10 mg/d as initial combination therapy with metformin extended-release (XR) significantly reduced glycated hemoglobin (A1C) from baseline to 24 weeks and allowed higher proportions of patients to achieve A1C
Dovepress open access to scientific and medical research
ORIGINAL RESEARCH
Open Access Full Text Article
Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies This article was published in the following Dove Press journal: Risk Management and Healthcare Policy 14 October 2016 Number of times this article has been viewed
Kelly F Bell Arie Katz John J Sheehan AstraZeneca, Wilmington, DE, USA
Correspondence: Kelly Bell Health Economics and Outcomes Research, AstraZeneca, US Medical Affairs, 1800 Concord Pike, PO Box 15437, Wilmington, DE, 19850, USA Tel + 1 267-417-6220 Email [email protected]
Background: The use of quality measures attempts to improve safety and health outcomes and to reduce costs. In two Phase III trials in treatment-naive patients with type 2 diabetes, dapagliflozin 5 or 10 mg/d as initial combination therapy with metformin extended-release (XR) significantly reduced glycated hemoglobin (A1C) from baseline to 24 weeks and allowed higher proportions of patients to achieve A1C
